文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

一项评估对乙酰氨基酚缓解重症疟疾儿童急性肾损伤的可行性、安全性和初步有效性的I/II期随机对照临床试验

A phase I/II randomized controlled clinical trial to assess the feasibility, safety, and preliminary effectiveness of paracetamol in resolving acute kidney injury in children with severe malaria.
PubMed 文献 · Trials · 2026-01-09

在乌干达东部开展I/II期开放标签平行随机对照试验,纳入40例疟疾所致急性肾损伤住院儿童,按1:1随机接受口服对乙酰氨基酚20 mg/kg每6小时一次共48小时或每30分钟温水擦浴直至退热。结果显示对乙酰氨基酚组48小时内肾脏恢复时间较对照组延长0.491小时(95%CI -9.265至10.248;p=0.921),差异无统计学意义;两组不良事件和肝毒性无显著差异。

要点

  • 对乙酰氨基酚组48小时内肾脏恢复时间较对照组延长0.491小时(95%CI -9.265至10.248;p=0.921),差异无统计学意义。
  • 调整年龄和体重后,对乙酰氨基酚组肾脏恢复时间较对照组延长1.04小时(95%CI -8.61至10.70;p=0.832),差异无统计学意义。
  • 安全性评估显示两组不良事件和肝毒性无显著差异。

核心结论

  • 对乙酰氨基酚虽安全,但未显著改善疟疾所致急性肾损伤儿童的肾脏恢复。
  • 需要进一步更大规模的研究来探索对乙酰氨基酚的这一作用。

研究设计与样本

  • I/II期开放标签平行随机对照试验,在乌干达东部纳入40例年龄>6个月至<12岁的疟疾所致急性肾损伤住院儿童。
  • 参与者按1:1随机接受口服对乙酰氨基酚20 mg/kg每6小时一次共48小时(n=20)或每30分钟温水擦浴直至退热(n=20)。
  • 仅主要结局评估者对干预设盲;主要结局为48小时肾脏恢复,采用限制性平均生存时间(RMST)在意向治疗人群中按随机分组评估。
  • 筛查时间为2021年9月19日至2023年8月25日,共筛查250例血红蛋白尿型重症疟疾儿童,最终入组40例。
  • 平均年龄为6.54(2.61)岁。

主要发现

  • 对乙酰氨基酚组48小时内肾脏恢复时间较对照组延长0.491小时(95%CI -9.265至10.248;p=0.921),差异无统计学意义。
  • 调整年龄和体重后,对乙酰氨基酚组肾脏恢复时间较对照组延长1.04小时(95%CI -8.61至10.70;p=0.832),差异无统计学意义。
  • 安全性评估显示两组不良事件和肝毒性无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步更大规模的研究来探索对乙酰氨基酚的这一作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute kidney injury (AKI) is prevalent among children with severe malaria, contributing to considerable morbidity and mortality. Oxidative stress has been implicated in the pathophysiology of malaria-induced AKI, and paracetamol, with its antioxidant properties, has been proposed as a solution. This phase I/II randomized trial evaluated paracetamol as a potential renoprotective adjunct in children with severe malaria and acute kidney injury. METHODS: We conducted a phase I/II open label parallel randomized controlled trial of 40 hospitalized children aged > 6 months to < 12 years with malaria-induced AKI in eastern Uganda. Participants were randomized by a sealed envelope 1:1 to receive either oral paracetamol 20 mg/kg 6 hourly for 48 h or tepid sponging every 30 min until fever subsided. Only the assessors of the primary outcome were masked to the intervention. The primary outcome was renal recovery at 48 h assessed using restricted mean survival time (RMST) in intention to treat population of children according to their randomization groups. RESULTS: Between 19 September 2021 and 25 August 2023, 250 children with hemoglobinuric severe malaria were screened and the 40 enrolled were randomly assigned paracetamol (n = 20) or tepid sponging (n = 20). The mean age was 6.54 (2.61) years. The mean time to renal recovery in the paracetamol group was 0.491 h (95% CI, -9.265 to 10.248; p = 0.921) longer than the control group within 48 h, but this difference was not statistically significant even after adjusting for age and weight: 1.04 h (95% CI, -8.61 to 10.70; p = 0.832). The safety assessment indicated no significant differences in adverse events and hepatotoxicity in either group. CONCLUSIONS: Although paracetamol was safe, it did not significantly improve renal recovery in children with malaria-induced AKI. Further larger studies are needed to explore this role of paracetamol. TRIAL REGISTRATION: ISRCTN84974248. Registered on August 12, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Paasi G, Namayanja C, Ongodia P, et al. A phase I/II randomized controlled clinical trial to assess the feasibility, safety, and preliminary effectiveness of paracetamol in resolving acute kidney injury in children with severe malaria. Trials. 2026. PMID: 41507938. doi:10.1186/s13063-026-09432-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。